ERBB2 and cancer: Interestingly the mean pCR rate reported in this meta-analysis was almost the same as in this study (19.2% vs 19.4%). HER2 is usually associated with more aggressive disease and a poor prognosis in 20-30% of patients with BC by making cancer cells escape from host immune surveillance [7].